References
- G Cristalli, S Costanzi, C Lambertucci, G Lupidi, S Vittori, R Volpini, and E Camaioni. (2001). Adenosine deaminase: Functional implications and different classes of inhibitors. Med Res Rev 21:105–128.
- TG Brady, and VJ Hegarty. (1966). An investigation of plant seeds for adenosine deaminase. Nature 209:1027–1028.
- ZY Chang, P Nygaard, AC Chinault, and RE Kellems. (1991). Deduced amino acid sequence of Escherichia coli adenosine deaminase reveals evolutionarily conserved amino acid residues: Implications for catalytic function. Biochemistry 30:2273–2280.
- PE Daddona. (1981). Human adenosine deaminase. Properties and turnover in cultured T and B lymphoblasts. J Biol Chem 256:12496–12501.
- MA Kelly, MM Vestling, CM Murphy, S Hua, T Sumpter, and C Fenselau. (1996). Primary structure of bovine adenosine deaminase. J Pharm Biomed Anal 14:1513–1519.
- D Shi, JH Winston, MR Blackburn, SK Datta, G Hanten, and RE Kellems. (1997). Diverse genetic regulatory motifs required for murine adenosine deaminase gene expression in the placenta. J Biol Chem 272:2334–2341.
- F Foss. (2003). Overview of cutaneous T-cell lymphoma: Prognostic factors and novel therapeutic approaches. Leuk Lymphoma 44 (Suppl 3):S55–S61.
- GC Mills, FC Schmalstieg, KB Trimmer, AS Goldman, and RM Goldblum. (1976). Purine metabolism in adenosine deaminase deficiency. Proc Natl Acad Sci U S A 73:2867–2871.
- R Hirschhorn. (1993). Overview of biochemical abnormalities and molecular genetics of adenosine deaminase deficiency. Pediatr Res 33:S35–S41.
- R Hirschhorn, F Martiniuk, and FS Rosen. (1978). Adenosine deaminase activity in normal tissues and tissues from a child with severe combined immunodeficiency and adenosine deaminase deficiency. Clin Immunol Immunopathol 9:287–292.
- K Borroto-Esoda, F Myrick, J Feng, J Jeffrey, and P Furman. (2004). In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 48:4387–4394.
- SM Daluge, SS Good, MB Faletto, WH Miller, MH St Clair, LR Boone, M Tisdale, NR Parry, JE Reardon, RE Dornsife, DR Averett, and TA Krenitsky. (1997). 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. Antimicrob Agents Chemother 41:1082–1093.
- E Fernandez, L Rodrigo, S Riestra, S Carcia, F Gutierrez, and G Ocio. (2000). Adenosine deaminase isoenzymes and neopterin in liver cirrhosis. J Clin Gastroenterol 30:181–186.
- HP Guan, MB Ksebati, YC Cheng, JC Drach, ER Kern, and J Zemlicka. (2000). Spiropentane mimics of nucleosides: Analogues of 2′-deoxyadenosine and 2′-deoxyguanosine. Synthesis of all stereoisomers, isomeric assignment, and biological activity. J Org Chem 65:1280–1290.
- G Iliakis, and FQ Ngo. (1985). Effects of adenosine deaminase inhibitor 2′-deoxycoformycin on the repair and expression of potentially lethal damage sensitive to beta-araA. Radiat Environ Biophys 24:81–88.
- JB Tunac, and M Underhill. (1985). 2′-Chloropentostatin: Discovery, fermentation and biological activity. J Antibiot (Tokyo) 38:1344–1349.
- T Sawa, Y Fukagawa, I Homma, T Takeuchi, and H Umezawa. (1967). Mode of inhibition of coformycin on adenosine deaminase. J Antibiot (Tokyo) 20:227–231.
- PW Woo, and DC Baker. (1982). Inhibitors of adenosine deaminase. Studies in combining high-affinity enzyme-binding structural units. erythro-1,6-Dihydro-6-(hydroxymethyl)-9-(2-hydroxy-3-nonyl)purine and erythro-9-(2-hydroxy-3-nonyl)purine. J Med Chem 25:603–605.
- RH Adamson, DW Zaharevitz, and DG Johns. (1977). Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2′-deoxycoformycin. Pharmacology 15:84–89.
- RP Agarwal, T Spector, and RE ParksJr. (1977). Tight-binding inhibitors–IV. Inhibition of adenosine deaminases by various inhibitors. Biochem Pharmacol 26:359–367.
- AJ Grant, and LM Lerner. (1979). Hexofuranosyladenine nucleosides as substrates and inhibitors of calf intestinal adenosine deaminase. J Med Chem 22:1016–1018.
- MM Oken, S Lee, NE Kay, W Knospe, and PA Cassileth. (2004). Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: A phase I/II study by the Eastern Cooperative Oncology Group study E1488. Leuk Lymphoma 45:79–84.
- HK Jun, TS Kim, and Y Yeeh. (1994). Purification and characterization of an extracellular adenosine deaminase from Nocardioides sp. J-326TK. Biotechnol Appl Biochem 20 (Pt 2):265–277.
- YK Shin, YH Park, JD Lee, and HK Jun. (1997). Identification of adenosine deaminase inhibitor-producing bacterium isolated from soil. J Microbiol Biotechnol 7:32–36.
- GL Tritsch. (1983). Validity of the continuous spectrophotometric assay of Kalckar for adenosine deaminase activity. Anal Biochem 129:207–209.
- T Mosmann. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63.
- H Tanaka, T Kawakami, ZB Yang, K Komiyama, and S Omura. (1989). Potentiation of cytotoxicity and antitumor activity of adenosine analogs by the adenosine deaminase inhibitor adecypenol. J Antibiot (Tokyo) 42:1722–1724.